Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1917-1922

  Mancuso, Andrea ^a   Giuliani, Rosa ^a   Accettura, Caterina ^a   Palma, Marzia ^a   D'Auria, Giuliana ^a   Cecere, Fabiana ^a   Paoluzzi, Luca ^a   Bezzi, Mario ^a   Massidda, Bruno ^b   Cortesi, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Arterial infusion; Colorectal cancer; Metastatic liver; Oxaliplatin

Indexed keywords

CISPLATIN; DEXAMETHASONE; HEPARIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEASIBILITY STUDY; FEMALE; HEPATITIS; HUMAN; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PEPTIC ULCER; PRIORITY JOURNAL; SCLEROSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 12444322664     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Fraumeni JG: Principles and Practice in Oncology, 1993.
2. Cunningham D and Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A, 15: 2077-79, 1993.
3. Kemey N and Fata F: Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. Hepatobiliary Pancreas Surg 6: 39-49, 1999.
4. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer Clin 49: 8-31, 1999.
5. Seifert JK, Junginger T and Morris DL: A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 43: 141-54, 1998.
6. August DA, Sugarbaker PH, Ottow RT, Gianola FJ and Schneider PD: Hepatic resection of colorectal metastases: influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 201: 210-8, 1985.
7. Borner MM: Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Ann Oncol 10, 6: 623-6, 1999.
8. Gilbert HA and Kagan AR: Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L, ed. Fundamental Aspects of Metastasis. Amsterdam: North-Hollan Publishing: 385-405, 1976.
9. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull ADM, Sullivan D, Stockman J, Blumgart LH and Fong Y: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases form colorectal cancer. New Engl J Med Vol 341 No 27: 2039-2048, 1999.
10. Scheele J, Stangl R and Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Brit J Surg 77(11): 1241-1246, 1990.
11. Steel G, Bleday R, Mayer RJ et al: A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group protocol 6584. J Clin Oncol 9(7): 1105-1112, 1991.
12. Scheele J, Stangl R, Altendorf-Hofmann A et al: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 110(1): 13-29, 1991.
13. Pedersen IK, Burcharth F, Roikjaer O et al: Resection of liver metastases from colorectal cancer: indications and results. Diseases of the Colon and Rectum 37(11): 1078-1082, 1994.
14. Harmon KE, Ryan JA Jr, Biehl TR et al: Benefits and safety of hepatic resection for colorectal metastases. Amer J Surg 177(5): 402-404, 1999.
15. Fong Y, Cohen AM, Fortner JG et al: Liver resection for colorectal metastases. J Clin Onc 15(3): 938-946, 1997.
16. Adson MA, van Heerden JA, Adson MH, Wagner JS and Ilstrup DM: Resection of hepatic metastases from colorectal cancer. Arch Surg 119: 647-51, 1984.
17. Hugues K, Scheele J and Sugarbaker PH: Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin North AM 69: 339-59, 1989.
18. Doci R, Gennari L, Bignami P, Montalto F, Marabito A and Bozzetti F: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78: 797-801, 1991.
19. Scheele J, Stangl R and Altendoff-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77: 1241-6, 1990.
20. Rosen CB, Nagorney DM, Taswell HF, Helgeson SL, Ilstrup DM, van Heerden JA and Adson MA: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 216: 493-505, 1992.
21. Nordlinger B, Guiguet M and Vaillant JC: Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77: 1254-62, 1996.
22. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W and Starzl TE: Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116: 703-11, 1994.
23. Rees M, Plant G and Bygrave S: Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 84: 1136-40, 1997.
24. Ackerman NB: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth Surgery 75: 589-96, 1974.
25. Ensminger WD and Gyves JW: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10: 176-82, 1983.
26. Ensiminger WD and Gyves JW: Regional chemotherapy of neoplastic diseases. Pharmacol Ther 21: 277-293, 1983.
27. Kenemy N, Daly J, Reichman B, Geller N, Botet J and Oderman P: Intra-hepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma - a randomized trial Am Inter Med 107: 459-65, 1987.
28. Hohn DC, Stagg RJ, Friedman MA et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northen California Oncology Group trial. J Clin Oncol 7: 1646-54, 1989.
29. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M and Steinberg SM: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-93, 1987.
30. Martin JK Jr, O'Connell MJ, Wieand HS et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 125: 1022-7, 1990.
31. Rougier P, Laplanche A, Huguier M et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112-8, 1992.
32. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-60, 1994.
33. Cvitkovic E and Chaney SG: Oxaliplatin: A new option for the treatment of colorectal cancer. Seminars in Oncology, Vol 25, No 2, Suppl 5 (April): 13-22, 1998.
34. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaimg D, Kunstlinger F, Levi F and Bismuth F: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol 8, 4: 347-53, 2001.
35. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL and Levi F: long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10, 6: 663-69, 1999.
36. Alberts SR, Horvath W, Donohue JH, Sternfeld W, Goldberg RM, Mahoney MR, Nagorney DM, Levitt R, Dakhil S, Rowland K and Sargent DJ: Oxaliplatin (OXAL), 5-Fluorouracil (5FU), and Leucovorin (CF) for patients (Pts) with liver only metastases (Mets) from colorectal cancer (CRC): A North Central Cancer Treatment Group (NCCTG) Phase II Study. Proc ASCO 2001; ab. 511.
37. Extra JM, Marty M, Brienza S and Misset JL: Pharmacokinetics and safety profile of Oxaliplatin. Seminars in Oncology, Vol 25, No 2, Suppl 5 (April): 13-22, 1998.
38. Watkins E, Khazei AM: Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 130(4): 581-605, 1970.
39. Curley SA, Chase JL, Roh MS and Hohn DC: Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 114(5): 928-35, 1993.
40. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
41. Creekmore SP, Urba WJ and Longo DL: Principles of the clinical evaluation of biologic agents. In: De Vita Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 67-86, 1991.
42. World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.
43. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F and Lersch C: The chemotherapeutic oxaliplatin alters voltage-grated Na+ channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32, 2000.
44. Jacox A, Carr DB, Payne R et al: Management of cancer pain: clinical practice guideline. No. 9. Rockville, Md.: Agency for Health Care Policy and Research, 1994. (AHCPR ublication no. 94-0592).
45. Principles of Analgesic use in the Treatment of Acute Pain and Chronic Cancer Pain. 3rd ed. Skokie, III: American Pain Society, 1992.
46. Twycross R: Pain Relief in Advanced Cancer. London: Churchill Livingstone, 1994.
47. Watson CPN: Antidepressant drugs as adjuvant analgesics. J Pain Symptom Manage 9: 392-405, 1994.
48. Rojagopalan M, Kurian G and Jacob J: Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 13: 738-41, 1998.
49. Kern W, Beckert B, Lang N, Waggershauser T, Braess J, Schalhorn A and Hiddemann W: Hepatic arterial infusion with Oxaliplatin, folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response, Anticancer Res 20(6D): 4973-5, 2000.
50. Ducreux M, Ychou M, Laplanche A, Gamelin E, Husseini F, Seitz J and Luboinski M: Intra-arterial hepatic chemotherapy with Oxaliplatin combined to intravenous treatment with 5FU + folinic acid in hepatic metastases of colorectal cancer. Ab 62 ECCO 2001.
51. Grage TB, Vassipoulow PP, Shingleton WW et al: Results of a prospective randomized study of hepatic artery infusion with 5 fluorouracil versus intravenous 5 fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group Study. Surgery 86: 550-555, 1979.
52. Roemeling R, Grage T and Hrushesky WJM: Circadian modified intraarterial treatment of colorectal carcinoma metastatic to the liver allows higher dose intensity to be safely given. Proc Am Soc Clin Oncol 8: 105, 1989 (abstr.)
53. Kenemy N, Niedzwiecki D, Shurgot B et al: Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment. Cancer 63: 742-747, 1989.
54. Balch CM, Urist MM, Soong SJ et al: A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 189: 567-573, 1983.
55. Niederhuber JE, Ensminger W Gyves J et al: Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336-1343, 1984.